# Huisheng Biopharmaceutical Co., Ltd: Pharmaceuticals, China

> Huisheng Biopharmaceutical Co., Ltd: Huisheng Biopharmaceutical Co Ltd Innovating Diabetes Care for a Healthier Future --About Us-- Huisheng...

Source: https://millionrounds.com/startup/huisheng-biopharmaceutical-co-ltd (Millionrounds; every figure on the page links to its filing or article)

China · [Pharmaceuticals startup](https://millionrounds.com/companies)

# Huisheng Biopharmaceutical Co., Ltd

Huisheng Biopharmaceutical Co Ltd Innovating Diabetes Care for a Healthier Future --About Us-- Huisheng Biopharmaceutical, headquartered in Jilin, China, is a pioneering company de

Funding reported Last round: Series A

Pharmaceuticals China

Company summary

- **Founded:** 2014 12 years old
- **Team:** 4 1 to 10 people
- **Funding reported:** 1.1B as listed, currency not stated
- **Last round:** Series A Jan 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Huisheng Biopharmaceutical Co., Ltd has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Huisheng Biopharmaceutical Co., Ltd

Huisheng Biopharmaceutical Co Ltd Innovating Diabetes Care for a Healthier Future --About Us-- Huisheng Biopharmaceutical, headquartered in Jilin, China, is a pioneering company de

dicated to the research, development, and manufacturing of high-quality insulin formulations and comprehensive diabetes treatments. With strong R&D capabilities, advanced production facilities, and a commitment to innovation, Huisheng is shaping the future of diabetes care by offering reliable, affordable, and globally accessible solutions. --Our Achievements-- Huisheng is proud to be the first company worldwide to successfully develop biosimilar versions of: *Insulin Degludec *Insulin Degludec & Aspart (70/30) Combination with high demanded traditional insulin products: *Insulin Aspart Injection *Insulin Aspart 30 Injection *Insulin Aspart 50 Injection These milestones demonstrate our industry leadership in insulin innovation and our ability to rapidly bring advanced therapies to market. --Comprehensive Diabetes Portfolio-- Huisheng provides a full spectrum of diabetes care solutions, including: Insulin formulations: Long-acting, rapid-acting, and premixed biosimilars Oral anti-diabetic medicines: Covering key small-molecule therapies and Next-generation GLP-1 therapies. Our integrated product pipeline enables us to support holistic diabetes management, from early intervention to long-term disease control. --Global Expansion-- Huisheng is actively expanding into international markets, with a special focus on Latin America, Asia, and the Middle East. We are building long-term partnerships through: *License-out *Finished product/API supply *Technology transfer collaborations Our mission is to ensure patients worldwide gain access to affordable, effective, and innovative diabetes therapies.

## What company datasets say Huisheng Biopharmaceutical Co., Ltd raised

Funding, as reported

Reported in all **1.1B** in the source's currency

Rounds **2**

Last round **Series A**

Last round size **79.8M**

Last round date **Jan 2023**

Investors listed **6**

## The company, in detail

What they build

Known for

glp1 medical insulin biosimilar insulin degludec antidiabetes insulin aspart pharmaceuticals pharmaceutical manufacturing semaglutide

Built with from their website

WOW Viewport Meta fullPage.js Mobile Friendly Tencent Exmail Bootstrap jQuery Swiper Animate.css Alibaba Cloud

+1 more

Modernizr

- **Sector:** Pharmaceuticals
- **Region:** Beijing
- **Revenue:** 35M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/huisheng-biopharmaceutical)

## Pharmaceuticals in China

Startups like it

- [**InventisBio** Shanghai · founded 2013 *Raised*](https://millionrounds.com/company/inventisbio)
- [**Alpha Biopharma** Shanghai · founded 2017 *Raised*](https://millionrounds.com/company/alpha-biopharma)
- [**IMPACT Therapeutics** founded 2009 *Raised*](https://millionrounds.com/company/impact-therapeutics)
- [**Naxions** Beijing · founded 2015 *Raised*](https://millionrounds.com/company/naxions)
- [**Laviana** Taizhou · founded 2003 *Raised*](https://millionrounds.com/company/laviana)
- [**Shanghai Cell Therapy Group** founded 2013](https://millionrounds.com/startup/shanghai-cell-therapy-group)
- [**Sinotau** founded 2005](https://millionrounds.com/startup/sinotau)
- [**HealSun Biopharm** Hangzhou · founded 2015](https://millionrounds.com/startup/healsun-biopharm)

## Is this your company?

Add your raise, your deck and your story, and put Huisheng Biopharmaceutical Co., Ltd in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)